BillionToOne, Inc.
BLLN
Rang in aandelen
#3441
BillionToOne, Inc. is a specialized diagnostics company that innovates by... BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Aandeelprijs
$105.11
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$4.96B
Verandering (1 dag)
1.56%
Verandering (1 jaar)
-
Land
US
Handel BillionToOne, Inc. (BLLN)
Categorie
Healthcare
Koersgeschiedenis voor BillionToOne, Inc. (BLLN)
Hoogste slotkoers: $100.39 op 2026-10-01
Laagste slotkoers: $106.24 op 2025-11-01
Laagste slotkoers: $106.24 op 2025-11-01
Koersgeschiedenis van BillionToOne, Inc. van 2025 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -1.87% |
| 2025 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $694.53 | 22.45% |
US
|
|
| $234.00 | 7.29% |
US
|
|
| $416.01 | 121.26% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $177.93 | 21.98% |
US
|
